We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+9.6%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$72.7B
AUM Growth
+$7.54B
(+12%)
Cap. Flow
-$3.34B
Cap. Flow
% of AUM
-4.6%
Top 10 Holdings %
Top 10 Hldgs %
23.55%
Holding
2,585
New
253
Increased
940
Reduced
728
Closed
298
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Crown Castle
CCI
|
+$536M |
| 2 |
Procter & Gamble
PG
|
+$358M |
| 3 |
CSX Corp
CSX
|
+$303M |
| 4 |
NVIDIA
NVDA
|
+$186M |
| 5 |
Eli Lilly
LLY
|
+$185M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NetEase
NTES
|
+$370M |
| 2 |
American Electric Power
AEP
|
+$338M |
| 3 |
Alibaba
BABA
|
+$322M |
| 4 |
Prologis
PLD
|
+$307M |
| 5 |
HEICO Corp
HEI
|
+$287M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.03% |
| 2 | Financials | 13.75% |
| 3 | Industrials | 12.1% |
| 4 | Healthcare | 10.45% |
| 5 | Consumer Discretionary | 7.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Rigel Pharmaceuticals
RIGL
$733M
| $2.94M | ﹤0.01% |
157,000
+22,637
| +17% | +$429K |
|
702
JFrog
FROG
$10.1B
| $2.94M | ﹤0.01% |
66,989
+10,258
| +18% | +$390K |
|
|
IFN
703
Aberdeen India Fund
IFN
$502M
| $2.91M | ﹤0.01% |
176,157
+69,338
| +65% | +$1.1M |
|
|
AVNS
704
DELISTED
Avanos Medical
AVNS
| $2.91M | ﹤0.01% |
237,615
+231,344
| +3,689% | +$2.91M |
|
705
TriMas Corp
TRS
$1.45B
| $2.89M | ﹤0.01% |
101,154
+98,983
| +4,559% | +$2.43M |
|
706
Laureate Education
LAUR
$5.14B
| $2.89M | ﹤0.01% |
123,722
-69,038
| -36% | -$1.48M |
|
707
CRISPR Therapeutics
CRSP
$4.99B
| $2.88M | ﹤0.01% |
59,333
-4,357
| -7% | -$169K |
|
708
Bank of N.T. Butterfield & Son
NTB
$2.44B
| $2.87M | ﹤0.01% |
64,739
+1,750
| +3% | +$71.6K |
|
709
Humana
HUM
$44.1B
| $2.86M | ﹤0.01% |
11,706
+11,062
| +1,718% | +$2.76M |
|
710
Vanguard Information Technology ETF
VGT
$147B
| $2.84M | ﹤0.01% |
34,232
| – | – |
|
711
Ryder
R
$10.1B
| $2.81M | ﹤0.01% |
17,698
+10,560
| +148% | +$1.55M |
|
712
Axos Financial
AX
$5.78B
| $2.79M | ﹤0.01% |
36,772
-5,675
| -13% | -$384K |
|
713
Toll Brothers
TOL
$14.1B
| $2.79M | ﹤0.01% |
24,462
-3,832
| -14% | -$398K |
|
714
Agilysys
AGYS
$3.03B
| $2.79M | ﹤0.01% |
24,331
+233
| +1% | +$21K |
|
715
Immunocore
IMCR
$1.75B
| $2.79M | ﹤0.01% |
+88,887
| New | +$2.76M |
|
716
Devon Energy
DVN
$47.4B
| $2.78M | ﹤0.01% |
87,317
+17,395
| +25% | +$554K |
|
|
MRX
717
Marex Group Limited Ordinary Shares
MRX
$4.48B
| $2.77M | ﹤0.01% |
+70,224
| New | +$2.92M |
|
|
CFLT
718
DELISTED
Confluent
CFLT
| $2.77M | ﹤0.01% |
111,061
+54,080
| +95% | +$1.22M |
|
719
Healthcare Services Group
HCSG
$1.51B
| $2.76M | ﹤0.01% |
183,948
+58,339
| +46% | +$774K |
|
|
FINV
720
FinVolution Group
FINV
$1.14B
| $2.74M | ﹤0.01% |
288,977
-7,193
| -2% | -$61.5K |
|
721
New Jersey Resources
NJR
$5.53B
| $2.73M | ﹤0.01% |
+60,888
| New | +$2.85M |
|
722
Dick's Sporting Goods
DKS
$17.8B
| $2.72M | ﹤0.01% |
13,767
+5,856
| +74% | +$1.09M |
|
|
GAP
723
The Gap Inc
GAP
$7.39B
| $2.7M | ﹤0.01% |
123,726
+73,516
| +146% | +$1.64M |
|
724
AdvanSix
ASIX
$543M
| $2.68M | ﹤0.01% |
112,741
+105,988
| +1,569% | +$2.4M |
|
|
SFD
725
Smithfield Foods
SFD
$9.87B
| $2.68M | ﹤0.01% |
+113,764
| New | +$2.51M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Lazard Asset Management held 2,585 positions worth $72.7B, up 12% from $65.1B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Lazard Asset Management withdrew a net $3.34B in Q2 2025, closing 298 positions and reducing 728 holdings. Its most notable exit was Eastman Chemical, an estimated $13.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Financials and Industrials.
Against the trend, Lazard Asset Management opened a new position in Arcos Dorados Holdings worth $117M.
- Lazard Asset Management's largest Q2 2025 buy was Arcos Dorados Holdings: 14,873,278 shares worth $117M.
- Lazard Asset Management added most to Crown Castle in Q2 2025, an estimated $536M increase.
- Lazard Asset Management's biggest Q2 2025 reduction was NetEase, cutting an estimated $370M.
- Lazard Asset Management fully exited Eastman Chemical in Q2 2025, selling an estimated $13.1M.
- Lazard Asset Management's ten largest holdings make up 24% of its $72.7B portfolio in Q2 2025.
- Lazard Asset Management opened 253 new positions and closed 298 in Q2 2025.
- Lazard Asset Management's portfolio value rose 12% quarter-over-quarter to $72.7B.
Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.